Sara Asimus

429 total citations
20 papers, 267 citations indexed

About

Sara Asimus is a scholar working on Physiology, Pharmacology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Sara Asimus has authored 20 papers receiving a total of 267 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Physiology, 7 papers in Pharmacology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sara Asimus's work include Asthma and respiratory diseases (10 papers), Pharmacogenetics and Drug Metabolism (6 papers) and Malaria Research and Control (5 papers). Sara Asimus is often cited by papers focused on Asthma and respiratory diseases (10 papers), Pharmacogenetics and Drug Metabolism (6 papers) and Malaria Research and Control (5 papers). Sara Asimus collaborates with scholars based in Sweden, United States and United Kingdom. Sara Asimus's co-authors include Michael Ashton, Trinh Ngoc Hai, Ulrika S. H. Simonsson, Doaa A. Elsherbiny, Nguyễn Văn Hướng, Max Petzold, Britt Jansson, Mats O. Karlsson, José Pedro Gil and Toufigh Gordi and has published in prestigious journals such as American Journal of Respiratory and Critical Care Medicine, Antimicrobial Agents and Chemotherapy and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Sara Asimus

18 papers receiving 256 citations

Peers

Countries citing papers authored by Sara Asimus

Since Specialization

Citations

This map shows the geographic impact of Sara Asimus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sara Asimus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sara Asimus more than expected).

Fields of papers citing papers by Sara Asimus

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sara Asimus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sara Asimus. The network helps show where Sara Asimus may publish in the future.

Co-authorship network of co-authors of Sara Asimus

This figure shows the co-authorship network connecting the top 25 collaborators of Sara Asimus. A scholar is included among the top collaborators of Sara Asimus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sara Asimus. Sara Asimus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Benralizumab in children with severe eosinophilic asthma: Pharmacokinetics and long‐term safety ( TATE study) 2024 ·Pediatric Allergy and Immunology ·H. James Wedner, Takao Fujisawa, Theresa W. Guilbert, Masanori Ikeda, Vinay Mehta, Jonathan S. Tam, (unknown), Sara Asimus, (unknown), James B. Johnston, Wendy I. White, (unknown), Viktoría Werkström, Maria Jison, (unknown)	16
2	Pharmacokinetics of AZD8630/AMG 104 inhaled anti-TSLP in healthy adults and asthma patients 2024 ·Sara Asimus, (unknown), Jason P. Cooper, Davinder Dosanjh, Xiaohong Zhou, Hitesh Pandya, Melanie T. Cushion, (unknown), Jane R. Parnes, Lubna Abuqayyas, Néstor A. Molfino, Sarah Doffman	1
3	Phase 1 Safety and Efficacy of AZD8630/AMG 104 Inhaled Anti-TSLP in Healthy Volunteers and Patients With Asthma on Medium-High Dose Inhaled Corticosteroid (ICS) and Long-Acting Beta-agonist (LABA) With Elevated Baseline Fractional Exhaled Nitric Oxide (FeNO) 2024 ·(unknown), Davinder Dosanjh, Muhammad Waqas Sadiq, Sara Asimus, Jonathan D. Cooper, Xiaohong Zhou, Henrik Seth, Hitesh Pandya, Dinesh Saralaya, Jutta Beier, (unknown), (unknown), Yasuhiro Matsunaga, Maria G. Belvisi, Néstor A. Molfino	2
4	Pharmacokinetics/pharmacodynamics of benralizumab in chronic rhinosinusitis with nasal polyps: Phase III, randomized, placebo‐controlled OSTRO trial 2024 ·British Journal of Clinical Pharmacology ·Claire Emson, Joseph K. Han, Claire Hopkins, Sara Asimus, Jennifer Cann, (unknown), Yuling Wu, Y. Sunila Reddy, Christopher McCrae, David Cohen, James L. Kreindler, Viktoría Werkström, Maria Jison, Martin Wagenmann, Claus Bachert	6
5	Diurnal variation in DLCO and non-standardized study procedures may cause a false positive safety signal in clinical trials 2021 ·Respiratory Medicine ·(unknown), Szilárd Nemes, Joanne Betts, (unknown), John Mo, Sara Asimus, Muhammad Waqas Sadiq, (unknown), Thomas Koernicke, Rainard Fuhr, (unknown), Christina Keen, (unknown), Jukka Mäenpää	0
6	Characterisation of pharmacokinetics, safety and tolerability in a first‐in‐human study for AZD8154, a novel inhaled selective PI3Kγδ dual inhibitor targeting airway inflammatory disease 2021 ·British Journal of Clinical Pharmacology ·Muhammad Waqas Sadiq, Sara Asimus, Maria G. Belvisi, (unknown), Rebecca Fransson, Rainard Fuhr, (unknown), Mahdi Hashemi, (unknown), (unknown), Christina Keen, (unknown), (unknown), Jukka Mäenpää, Sofia Necander, Szilárd Nemes, Joanne Betts	12
7	A Phase 2a, Double-Blind, Placebo-controlled Randomized Trial of Inhaled TLR9 Agonist AZD1419 in Asthma 2020 ·American Journal of Respiratory and Critical Care Medicine ·Ioannis Psallidas, Vibeke Backer, Piotr Kuna, Robert Palmér, Sofia Necander, (unknown), (unknown), (unknown), Mahdi Hashemi, Per Gustafson, Sara Asimus, Stephen Delaney, Katerina Pardali, (unknown), J.O. Almquist, Sam Jackson, Robert L. Coffman, (unknown), Tariq Sethi	17
8	Safety, Tolerability and Pharmacokinetics (PK) of AZD8154, A Selective PI3Kγδ Inhibitor, After Single and Multiple Ascending Inhaled Doses in Healthy Volunteers 2020 ·Sara Asimus, (unknown), (unknown), (unknown), Jukka Mäenpää, Rainard Fuhr, Thomas Koernicke, Sofia Necander, (unknown), Szilárd Nemes, Christina Keen, (unknown), Joanne Betts	2
9	Pharmacokinetics, pharmacodynamics and safety of the inverse retinoic acid‐related orphan receptor γ agonist AZD0284 2020 ·British Journal of Clinical Pharmacology ·Sara Asimus, Robert S. Palmer, Muna Albayaty, (unknown), Christina Lundin, Marita Olsson, Rikard Pehrson, John Mo, Muir Russell, Sara Carlert, (unknown), (unknown)	9
10	Safety, tolerability and pharmacokinetics (PK) of AZD8154 (a selective PI3K?d inhibitor) after single ascending inhaled doses in healthy volunteers 2019 ·(unknown), Sara Asimus, (unknown), (unknown), Jukka Mäenpää, Barbara Valastro, Rainard Fuhr, Thomas Koernicke, Christina Keen, (unknown), Joanne Betts	2
11	Reducing the variability of DLCO measurements in clinical trials 2019 ·(unknown), Joanne Betts, (unknown), John Mo, Sara Asimus, (unknown), Thomas Koernicke, Rainard Fuhr, (unknown), Christina Keen, Jukka Mäenpää	1
12	AZD7624, an Inhaled p38 Inhibitor, Demonstrates Local Lung Inhibition of LPS-Induced TNFα with Minimal Systemic Exposure 2018 ·Journal of Pharmacology and Experimental Therapeutics ·Rikard Pehrson, (unknown), Danen Cunoosamy, Sara Asimus, (unknown), Naimish Patel, Annika Borde, (unknown)	4
13	Tolerability in man following inhalation dosing of the selective TLR7 agonist, AZD8848 2016 ·BMJ Open Respiratory Research ·Stephen Delaney, Mark Biffen, (unknown), John Bell, Sara Asimus, Ajay Aggarwal, Maarten C. Kraan, (unknown)	18
14	PXR Variants and Artemisinin Use in Vietnamese Subjects: Frequency Distribution and Impact on the Interindividual Variability of CYP3A Induction by Artemisinin 2012 ·Antimicrobial Agents and Chemotherapy ·(unknown), Elke Schaeffeler, Stefan Winter, Sara Asimus, Matthias Schwab, Michael Ashton, Oliver Burk, José Pedro Gil	10
15	Artemisinin–a possible CYP2B6 probe substrate? 2009 ·Biopharmaceutics & Drug Disposition ·Sara Asimus, Michael Ashton	9
16	A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens 2008 ·Journal of Pharmacokinetics and Pharmacodynamics ·Doaa A. Elsherbiny, Sara Asimus, Mats O. Karlsson, Michael Ashton, Ulrika S. H. Simonsson	30
17	Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam 2008 ·European Journal of Clinical Pharmacology ·María Isabel Veiga, Sara Asimus, Pedro Eduardo Ferreira, José Paulo Martins, Isa Cavaco, Vera Ribeiro, Trinh Ngoc Hai, Max Petzold, Anders Björkman, Michael Ashton, José Pedro Gil	40
18	Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects 2007 ·Fundamental and Clinical Pharmacology ·Sara Asimus, Doaa A. Elsherbiny, Trinh Ngoc Hai, Britt Jansson, Nguyễn Văn Hướng, Max Petzold, Ulrika S. H. Simonsson, Michael Ashton	59
19	Artemisinin and CYP2A6 activity in healthy subjects 2007 ·European Journal of Clinical Pharmacology ·Sara Asimus, Trinh Ngoc Hai, Nguyễn Văn Hướng, Michael Ashton	20
20	Retrospective analysis of artemisinin pharmacokinetics: application of a semiphysiological autoinduction model 2006 ·British Journal of Clinical Pharmacology ·Sara Asimus, Toufigh Gordi	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact